Ethris’ goal is to become the leader in inhaled mRNA therapeutics and next-generation mRNA vaccines.
Ethris is actively seeking to forge strategic partnerships and licensing arrangements with companies, mid and large size, that share our vision of advancing the development of innovative mRNA-based vaccines and therapies. Of interest are:
- Out-licensing Opportunities
- Product-development Partnerships
- Technology Collaborations